CONTACT US
45-1 Ramsey Road, Shirley, NY 11967, USA
USA: 1-631-871-5806
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Anti-GD2 CAR-T Preclinical in vivo Assay

Target Background

Disialoganglioside GD2 is a glycolipid antigen involving in adhesion of tumor to extracellular matrix proteins. Previous studies indicate GD2 has limited expression on normal tissues such as central nervous system, peripheral nerves and skin melanocytes, but is highly expressed on surface of tumor cells. Therefore, GD2 has been recognized as a valuable therapeutic target of human cancer such as neuroblastoma and melanoma.

Anti-GD2 CAR-T Preclinical in vivo Assay

Anti-GD2 CAR-T Cell Therapy

Several Phase I clinical trials have been initiated to evaluate anti-GD2 CAR-T cells in patients of neuroblastoma, melanoma and GD2-positive sarcoma (NCT02107963, NCT02439788, NCT01953900 and NCT02482532). Results from completed trial indicate that GD2 specific CAR-T cells can induce complete tumor responses in patient with active neuroblastoma and extensive persistence of in patients (NCT01460901).

Creative Biolabs fully understand researches of adoptive T cell therapy targeting GD2 are time-consuming and costly. With our highly experienced technical groups and state-of-the-art facilities, Creative Biolabs can accelerate this process by providing approved in vivo tumor models and related evaluation services.

Animal Models for in vivo Study of anti-GD2 CAR-T Cell Therapy

With supports from experienced technical team, Creative Biolab offers various tumor models for GD2 specific CAR-T therapy evaluation. All animal experiments are monitored under an approved Institutional Animal Care and Use Committee (IACUC) protocol.
Xenograft model of human neuroblastoma
NOD/SCID mice are subcutaneously injected (or via tail vein for systemic tumor studies) human neuroblastoma cells SH-SY5Y on right or left flank, followed by local injection of GD2 specific CAR-T cells and intraperitoneal injection of rhIL-2.
Xenograft model of human colon carcinoma
Immunocompromised mice bred in Creative Biolabs are subcutaneously inoculated with colon carcinoma cell CT26 and then receive injection of GD2 specific CAR-T cell via tail vein. Tumor sizes of mice are monitored using electronic calipers, body weight and other physiological signs are also recorded.

In vivo Assay Parameters and Techniques

Creative Biolabs offers comprehensive services to evaluate anti-GD2 CAR-T therapy. Our technical group is very experienced and strive to finish each milestone within proposed timeline.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Histopathology
Tumorigenicity Study
GLP-Compliant Preclinical Test
All our experiments are performed by well-trained and experienced technicians in a GLP-compliant and IACUC-regulated facility.

References

  1. Singh, et al. "Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma." Cancer immunology research 2.11 (2014): 1059-1070.

Online Inquiry

Name:
Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.
CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

Europe
Ringstrasse 4, 64401 Gross-Bieberau, Germany
Tel: 44-207-097-1828

Distributors

To view the contact information for a specific location, select the desired country:

Australia
australia

FOLLOW US ON